Paul Eliadis

1.1k total citations
14 papers, 181 citations indexed

About

Paul Eliadis is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Paul Eliadis has authored 14 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Hematology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Paul Eliadis's work include Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Paul Eliadis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Chronic Myeloid Leukemia Treatments (5 papers). Paul Eliadis collaborates with scholars based in Australia, United States and United Kingdom. Paul Eliadis's co-authors include Marilyn Chapman, Luther C. Jones, Ian Bunce, Leigh C. Ward, Frédéric Peyrade, Kerry Taylor, Ka Lung Wu, Radhakrishnan Ramchandren, Robert Chen and Karl Eckert and has published in prestigious journals such as Blood, Journal of Hematology & Oncology and Journal of Thoracic Oncology.

In The Last Decade

Paul Eliadis

13 papers receiving 170 citations

Peers

Paul Eliadis

ONCOL

GENET

PFM

HEMAT

Pat Stiff United States

Ana Jiménez Ubieto Spain

Ana Isabel Teruel Spain

Vahid Asnafi France

G Perea Spain

Francesca Maria Quaglia Italy

Michela Ansuinelli Italy

Silja Mack Germany

Stephen M. Ansell United States

Elisabet Björklund Sweden

Pat Stiff United States

Paul Eliadis

89 ×0.9

ONCOL

68 ×0.8

GENET

73 ×1.3

PFM

90 ×1.8

HEMAT

19 ×0.6

Citations per year, relative to Paul Eliadis Paul Eliadis (= 1×) peers Pat Stiff

Countries citing papers authored by Paul Eliadis

Since Specialization

Citations

This map shows the geographic impact of Paul Eliadis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Eliadis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Eliadis more than expected).

Fields of papers citing papers by Paul Eliadis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Eliadis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Eliadis. The network helps show where Paul Eliadis may publish in the future.

Co-authorship network of co-authors of Paul Eliadis

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Eliadis. A scholar is included among the top collaborators of Paul Eliadis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Eliadis. Paul Eliadis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Sandler, Carolina X., Rosalind R. Spence, Tamara L. Jones, et al.. (2023). The safety, feasibility, and efficacy of an 18-week exercise intervention for adults with primary brain cancer – the BRACE study. Disability and Rehabilitation. 46(11). 2317–2326. 5 indexed citations

Wang, Michael, Radhakrishnan Ramchandren, Robert Chen, et al.. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology & Oncology. 14(1). 179–179. 39 indexed citations

Tam, Constantine S., Radhakrishnan Ramchandren, Robert Chen, et al.. (2020). Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study. Blood. 136(Supplement 1). 39–41. 5 indexed citations

Wang, M., Lionel Karlin, Wojciech Jurczak, et al.. (2019). RESULTS FROM THE SAFETY RUN‐IN PERIOD OF THE SYMPATICO STUDY EVALUATING IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. Hematological Oncology. 37(S2). 333–335. 3 indexed citations

Roberts, Kate, et al.. (2017). P2.07-033 Anti-PD1-Induced Rotator Cuff Injury: A Case Series. Journal of Thoracic Oncology. 12(11). S2428–S2428.

Forsyth, Cecily, David Gómez‐Almaguer, Paul Eliadis, et al.. (2013). A Multicenter, Open-Label, Noncomparative Screening Study of Enzastaurin in Adult Patients With Non-Hodgkin Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 13(4). 398–403. 2 indexed citations

Forsyth, Cecily, Paul Eliadis, Stephanie Roberson, et al.. (2009). Enzastaurin in Patients with Non-Hodgkin Lymphomas: A Multicenter, Open-Label, Screening Study.. Blood. 114(22). 3719–3719. 3 indexed citations

Taylor, Kerry, et al.. (2001). Angioedema in the emergency department: A presentation of lymphoma. Emergency Medicine. 13(4). 465–468. 4 indexed citations

Bentley, Michael A., Kerry Taylor, Andrew Grigg, et al.. (1999). Long-Term Interferon-Alpha 2A Does not Induce Sustained Hematologic Remission in Younger Patients with Essential Thrombocythemia. Leukemia & lymphoma. 36(1-2). 123–128. 11 indexed citations

10.

Mills, Anthony K., Kerry Taylor, Susan Wright, et al.. (1999). Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Australian and New Zealand Journal of Medicine. 29(1). 29–35. 25 indexed citations

11.

Lowenthal, RM, JP Matthews, Ralph Cobcroft, et al.. (1999). A Phase I/II Study of Intensive Dose Escalation of Cytarabine in Combination with Idarubicin and Etoposide in Induction and Consolidation Treatment of Adult Acute Myeloid Leukemia. Leukemia & lymphoma. 34(5-6). 501–510. 6 indexed citations

12.

Gill, Devinder, et al.. (1997). 053 2-Chlorodeoxyadenosine as initial therapy in chronic lymphocytic leukaemia. 39(S1). S83–S102. 1 indexed citations

13.

Taylor, Kerry, R. Rodwell, Debra L. Taylor, et al.. (1995). Normal (RT-PCR negative) stem cells can be collected following lenograstim therapy in chronic myeloid leukemia (CML) in major/complete cytogenetic response (MCR/CCR) on alpha-interferon (alpha-IFN).. Blood. 86(10). 3955–3955. 1 indexed citations

14.

Bunce, Ian, et al.. (1995). Psychosocial benefits of postmastectomy lymphedema therapy. Cancer Nursing. 18(3). 197???205–197???205. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact